Soffer Gad 4
4 · Atara Biotherapeutics, Inc. · Filed Nov 17, 2017
Insider Transaction Report
Form 4
Soffer Gad
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2017-11-15+4,146→ 263,236 total - Sale
Common Stock
2017-11-17$15.00/sh−7,000$105,000→ 256,236 total - Exercise/Conversion
Restricted Stock Units
2017-11-15−4,146→ 2,764 total→ Common Stock (4,146 underlying)
Footnotes (5)
- [F1]Shares issued upon settlement of vested restricted stock units ("RSUs").
- [F2]Transaction pursuant to Rule 10b5-1 Plan adopted September 26, 2016.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- [F4]The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date.
- [F5]The earlier of (i) January 10, 2021 or (ii) the recipient's termination date.